GSK: starts phase 2/3 study of Covid-19 antibody treatment
(CercleFinance.com) - A first patient was dosed last week in a phase 2/3 study with GSK and Vir Biotechnology's monoclonal antibody for the early treatment of Covid-19 in patients who are at high risk of hospitalisation, the companies said on Monday.
The aim of the study, which will enrol approximately 1,300 patients worldwide, is to assess whether VIR-7831 can prevent hospitalisation due to COVID-19.
Initial results may be available before the end of this year, with complete results expected in the first quarter of 2021, and potentially early access to the antibody treatment as soon as the first half of 2021.
The follows the signing of a collaboration between GSK and Vir, a US-based immunology firm in April 2020 to research and develop treatments for coronaviruses.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The aim of the study, which will enrol approximately 1,300 patients worldwide, is to assess whether VIR-7831 can prevent hospitalisation due to COVID-19.
Initial results may be available before the end of this year, with complete results expected in the first quarter of 2021, and potentially early access to the antibody treatment as soon as the first half of 2021.
The follows the signing of a collaboration between GSK and Vir, a US-based immunology firm in April 2020 to research and develop treatments for coronaviruses.
Copyright (c) 2020 CercleFinance.com. All rights reserved.